

## **CURRICULUM VITAE**

**HARRIS EMILIO FOSTER JR., M.D.**

### **EDUCATION**

1976-1979	North Miami Beach Senior High School Miami, Florida	Liberal Arts
-----------	---	--------------

### **UNDERGRADUATE**

Sept 1979-Aug 1983	University of Michigan Ann Arbor, Michigan	B.S. Degree in Biology
--------------------	---	------------------------

### **MEDICAL SCHOOL**

Sept 1983-June 1987	University of Miami School of Medicine Miami, Florida	M.D. Degree with honors
---------------------	---	-------------------------

### **GRADUATE TRAINING**

July 1987-June 1988	University of Michigan Ann Arbor, Michigan	Intern in Surgery
---------------------	---	-------------------

July 1988-June 1989	University of Michigan Ann Arbor, Michigan	Resident in Surgery
---------------------	---	---------------------

July 1989-June 1992	University of Michigan Ann Arbor, Michigan	Resident in Urology
---------------------	---	---------------------

## **HOSPITAL/ACADEMIC APPOINTMENTS**

Aug 1992-June 1997	Yale University School of Medicine Assistant Professor of Surgery Section of Urology
Oct 1992-present	West Haven Veterans Administration Hospital Urology Consultant
Oct 1992-present	Gaylord Rehabilitation Hospital Urology Consultant
July 1997-present	Yale University School of Medicine Associate Professor of Surgery Section of Urology
March 2003-present	Hospital for Special Care Medical Staff Consultant in Urology

## **CERTIFICATES AND LICENSURE**

1987-1993	State of Michigan Medical License
1986	Basic and Advanced Cardiac Life Support
1991	Microsurgery Course - University of Louisville (Kentucky)
1992-present	State of Connecticut Medical License
1992-present	Drug Enforcement Agency License
1994-present	Diplomate American Board of Urology

## **HONORS AND AWARDS**

1983-1987	Alumni Scholarship - University of Miami School of Medicine
1985	George Tershakovic Award - University of Miami School of Medicine (Given to second year medical student with highest National Board of Medicine score in Biochemistry)
1986	Alpha Omega Alpha National Medical Honor Society
1999	Boehringer-Ingelheim Pharmaceutical Company Urology Teaching Award

## **MEMBERSHIPS**

1980-present	Kappa Alpha Psi Fraternity (President University of Michigan chapter 1982-1983)
1983-1987	American Medical Student Association
1983-1987	National Medical Student Association (Vice-president University of Miami School of Medicine chapter 1986-1987)
1991-present	National Medical Association
1991-present	American Urological Association (AUA)
1992-present	American Cancer Society (Connecticut Chapter)
1992-present	Yale Comprehensive Cancer Center
1993-present	Society for Female Urology and Urodynamics
1994-present	New England Section of AUA
1995-present	Connecticut Chapter Multiple Sclerosis Society Advisory Committee
1996-present	National Association for Continence
1997-present	Yale Surgical Society
1997-present	Sigma Xi Scientific Research Society
1997-present	Society of University Urologists
1998-present	Female Urology and Neurourology (FUN) Group
1998-present	Doxazosin Investigators and Consultants Educational Exchange (DICE)
1999-present	Societe Internationale D'Urologie

## **COMMITTEE ASSIGNMENTS**

1992-present	Chair of resident selection committee Yale Urology
1994	Scientific Program Committee New England Section of the AUA

1994-1996	Co-chairman Recruitment and Retention Committee for Full Scale NIH-BPH Study
1995	Co-chairman Scientific Program Committee New England Section of the AUA
1996-present	Scientific Program Committee. New England Section of the AUA
1997-2002	Editorial Board, Investigative Urology section in Journal of Urology
1997	Study Section National Institutes of Health/Human Genome Research Institute for review of Collaborative Recruitment Centers for African American Hereditary Prostate Cancer Study Network
1999-2003	American Board of Urology Examination Committee
1999-present	The Edwin Beer Selection Committee The New York Academy of Medicine
1999-2001	Connecticut Representative to New England Section of the AUA
1999-2001	New England Section representative to the American Urological Association Research Committee
April 2001	Study Section National Institutes of Health/National Institute of Child Health and Human Development for review of applications for RFA entitled "Epidemiologic research on female pelvic floor disorders".
July 2001	Chairman of Muscle Group. National Institutes of Health Bladder Research Progress Review Group.
2001-2003	Chairman National Institutes of Health Interstitial Cystitis Clinical Trials Group (ICCTG)
2001-2002	By-Laws Committee. New England Section of the AUA
2003-2004	Judicial and Ethics Committee. New England Section of the AUA
2003-present	Chairman, National Institutes of Health Interstitial Cystitis Clinical Research Network (ICCRN)

## EDUCATIONAL COURSES

12/6-8/1997	AUA Urodynamics Course Faculty Member
3/14-15/1998	Houston, Texas
9/12-13/1998	
3/20-21/1999	
11/5-6/1999	
3/24-26/2000	
3/9-11/2001	
3/2-3/2002	
3/15-16/2003	
4/17-18/2004	

## PUBLICATIONS

### Manuscripts

1. **Foster HE Jr**, Ritchey ML and Bloom DA: Adventitious Knots in Urethral Catheters: Report of 5 cases. J Urol 148: 1496, 1992.
2. **Foster HE Jr** and McGuire EJ: Management of urethral obstruction with transvaginal urethrolysis. J Urol 150: 1448, 1993.
3. Saito M, Yoshida M, Fukumoto Y, **Foster HE Jr**, Mutoh S, Weiss RM and Latifpour J: Light microscopic localization of muscarinic receptors in diabetic and diuretic rat bladder. Can J Physiol Pharmacol 72: 535, 1994.
4. Jayson MA and **Foster HE Jr**: Management of urologic emergencies for non-urologists. Resident and Staff Physician. Resident and Staff Physician 41: 13, 1995.
5. Smith SD, Wheeler MA, **Foster HE Jr**, and Weiss RM: Urinary nitric oxide synthase and cyclic GMP levels are decreased with interstitial cystitis and increased with urinary tract infections. J Urol 155: 1432-1435, 1996.
6. Saito M, Nishi K, **Foster HE Jr**, Weiss RM, and Latifpour J: Effect of experimental diabetes on rat prostate endothelin receptors. European Journal of Pharmacology 310: 197-200, 1996.
7. **Foster HE Jr**, Smith SD, Wheeler MA and Weiss RM: Nitric oxide and interstitial cystitis. Advances in Urology. 10: 1-25, 1997.
8. Smith SD, Wheeler MA, **Foster HE Jr**, and Weiss RM: Improvement in interstitial cystitis symptom scores during treatment with oral L-arginine. J Urol 158: 703-708, 1997.
9. Swana HS and **Foster HE Jr**: Erosion of malleable penile prosthesis into bladder. J Urol 157: 2259-2260, 1997.

10. Wheeler MA, Smith SD, Saito N, **Foster HE Jr**, and Weiss RM: Effect of long term oral L-arginine on the nitric oxide synthase pathway in the urine from patients with interstitial cystitis. *J Urol* 158: 2045-2050, 1997.
11. Saito M, **Foster HE Jr**, Wada Y, Myagawa I, Weiss RM and Latifpour J: Endothelin receptors in diabetic rat bladder dome. *Neurourol Urodynam* 16: 373-374, 1997.
12. Neitlich JD, **Foster HE Jr**, Glickman MG, and Smith RC: Detection of urethral diverticula using a high resolution fast spin echo technique: comparison with double balloon urethrography. *J Urol* 159: 408-410, 1998.
13. **Foster HE Jr.**: In favor of open bladder neck suspension for the treatment of female stress urinary incontinence. *Contemporary Urology* 10: 63-70, 1998.
14. Nishi K, Wada Y, Saito M, **Foster HE Jr**, Weiss RM, and Latifpour J: Properties of alpha-1 adrenergic receptors in the rat prostate: effect of experimental diabetes. *Urologia Internationalis* 61: 147-153, 1998.
15. Nishi K, Latifpour J, Saito M, **Foster HE Jr**, Yoshida M, and Weiss RM: Characterization, localization and distribution of alpha-1 adrenoceptor subtype in male rabbit urethra. *J Urol* 160: 196-205, 1998.
16. Saito S, Wada Y, Wang ZJ, **Foster HE Jr**, Smith SD, Nishi K, Weiss RM and Latifpour J. Gene Expression, localization, and pharmacological characterization of endothelin receptors in diabetic rat prostate. *J Urol* 161: 350, 1999.
17. **Foster HE Jr**, Wang ZJ, Wada Y, Smith SD, Saito S, Weiss RM and Latifpour J. Expression and localization of basic fibroblast growth factor in diabetic rat prostate. *J Urol* 161:231, 1999.
18. Korting GE, Smith SS, Wheeler MA, Weiss RM and **Foster HE Jr**: A randomized double-blind trial of oral L-arginine for treatment of interstitial cystitis. *J Urol* 161: 558-565, 1999.
19. **Foster HE Jr.**: Urologic causes of pelvic pain. *Infertility Reproductive Clinics N Amer.* 10: 701-715, 1999.
20. Cooperberg MR, Chambers SK, Rutherford TJ, and **Foster HE Jr**: Cystic pelvic pathology presenting as falsely elevated post void residual urine measured by portable ultrasound bladder scanning: report of 3 cases and review of the literature. *Urology* 55: 590, 2000.
21. Saito M, Wada Y, Ikeda K, Wang ZJ, Smith SD, **Foster HE Jr**, Nishi K, Weiss RM, and Latifpour J. Gene expression, localization, and pharmacological characterization of endothelin receptors in diabetic rat bladder dome. *Eur J Pharmacol* 387:253-263, 2000
22. Wang Z-J, Ikeda K, Wada Y, **Foster HE Jr**, Smith SD, Weiss RM and Latifpour J: Effects of experimental diabetes on the expression and localization of basic fibroblast growth factor in the rat prostate. *Br J Urol* 85: 945-952, 2000.

22. Saito M, Wada Y, Ikeda K, Wang Z-J, **Foster HE Jr**, Smith SD, Weiss RM, and Latifpour J: Diabetes-induced changes in the expression of endothelin receptor subtypes and their respective messenger RNAs in rat prostate. *Mol Cell Biochem* 210: 1-12, 2000.
23. Ikeda K, Wada Y, Pasha MS, Wang Z-J, **Foster HE Jr**, Yoshida, M, Weiss RM and, Latifpour J.: Upregulation of transforming growth factor-beta and its receptors at both protein and gene transcript levels is associated with prostatic regression in the experimental diabetic rat. *J Urol* 163: 211, 2000.
22. Ikeda K, Wada Y, Wang Z-J, **Foster HE Jr**, Weiss RM and, Latifpour J. Experimental diabetes-induced regression of the rat prostate is associated with an increased expression of transforming growth factor- $\beta$ . *J Urol* 164: 180-185, 2000.
23. Saito M, Wada Y, Ikeda K, Wang Z, Smith SD, **Foster HE Jr**, Nishi K, Weiss RM, and Latifpour J: Gene expression, localization, and pharmacological characterization of endothelin receptors in diabetic rat bladder dome. *Eur J Pharm* 387: 253-263, 2000.
24. Olsson LE, Anderson KR, and **Foster HE Jr**: Small bowel perforation after extracorporeal shock wave lithotripsy. *J Urol* 164: 775, 2000.
25. Ikeda K, Wada Y, Sanematsu H, **Foster HE Jr**, Shin D, Weiss RM, and Latifpour J: Regulatory effect of experimental diabetes on the expression of endothelin receptor subtypes and their gene transcripts in the rat adrenal gland. *J Endocrinol.* 168: 163-175, 2001
26. Kusek JW, Ahrens A, Burrows PK, Clarke HS, **Foster HE Jr**, Hanson K, Jacobs SC, Kirkemo A, O'Berry K and Pavlik VNI: Recruitment for a clinical trial of drug treatment for benign prostatic hyperplasia. *Urol* 59(1): 63-7, Jan 2002
27. **Foster HE Jr**: Bladder symptoms and multiple sclerosis. *Multiple Sclerosis Quarterly Report* 21 (1): 5-8, Spring 2002
28. Takahashi W, Afiatpour P, **Foster HE Jr**, Ikeda K, Wada Y, Weiss RM and Latifpour J. The effect of castration on endothelins, their receptors and endothelin converting enzyme in rat prostate. *Naunyn-Schmiedeberg's Arch Pharmacol* 366: 166-76, 2002
29. **Foster HE Jr**: Urinary tract infections (UTIs) and multiple sclerosis: Connection Between UTIs and Neurological Progression. *Multiple Sclerosis Quarterly Report* 21 (2): 1-4, Summer 2002
30. Afiatpour P, Latifpour J, Takahashi W, Yono M, **Foster HE Jr**, Ikeda K, Pouresmail M and Weiss RM. Developmental changes in the functional, biochemical and molecular properties of rat bladder endothelin receptors. *Naunyn-Schmiedeberg's Arch Pharmacol* 367: 462-72, 2003
31. Yono M, Takahashi W, Pouresmail M, Johnson D, **Foster HE Jr**, Weiss RM, and Latifpour J. Quantification of endothelins, their receptors and endothelin converting enzyme mRNAs in

rat genitourinary tract using real-time RT-PCR. *J of Pharmacological and Toxicological Methods* 48 (2) 87-95, 2002

32. McConnell JD, Roehrborn CG, Bautista OM, Andriole GL Jr, Dixon CM, Kusek JW, Lepor H, McVary KT, Nyberg LM Jr, Clarke HS, Crawford ED, Diokno A, Foley JP, **Foster HE Jr**, et al. The Long-Term Effect of Doxazosin, Finasteride, and Combination Therapy on the Clinical Progression of Benign Prostatic Hyperplasia. *NEJM* 349 (25) 2385-2396, 2003.

33. Yono M, Latifpour J, Pouresmail M, Takahashi W, **Foster HE Jr**, Afiatpour P and Weiss R. Age-related changes in the properties of the endothelin receptors system at protein and mRNA levels in the rat vas deferens. *J Rec Sign Transduc Res*, 24: 53-66, 2004.

33. **Foster HE Jr**, Yono M, Shin D, Takahashi W, Pouresmail M, Afiatpour P, and Latifpour J. Effects of chronic administration of doxazosin on alpha 1-adrenoceptors in the rat prostate. *J Urol* (in press 2004)

34. Yono M, **Foster HE Jr**, Shin D, Pouresmail M, Takahashi W, Latifpour J. Doxazosin-induced up-regulation of alpha 1-adrenoceptor mRNA in the rat lower urinary tract. *Can J Physiol and Pharmacol* (in press).

35. Yono M, **Foster HE Jr**, Shin D, Takahashi W, Pouresmail M, and Latifpour J. Chronic doxazosin administration causes an up-regulation of alpha 1-adrenoceptor mRNA in the rat genitourinary tract. *FASEB J.* (in press 2004)

35. Mayer R, Propert KJ, Peters KM, Payne CK, Zhang Y, Burks D, Culkin DJ, Diokno A, Hanno P, Landis JR, Madigan R, Nickel JC, Sant G, Warren J, Kusek JW, Nyberg LM, **Foster HE Jr**, et al. A randomized controlled trial of intravesical bacillus calmette guerin for treatment refractory interstitial cystitis. (Submitted for publication 2004)

36. Yono M, **Foster HE Jr**, Shin D, Takahashi W, Pouresmail M, and Latifpour J. Doxazosin treatment causes differential alterations of alpha 1 adrenoceptor subtypes in rat kidney, heart and aorta. *Life Sciences.* (in press 2004)

37. Yono M, **Foster HE Jr**, Shin D, Mane S, Weiss RM, Latifpour J. Molecular classification of Doxazosin-induced alterations by gene expression profiling. *Life Sciences.* Submitted.

## **Editorials**

1. **Foster HE Jr**: Re: The efficacy of urethrolisis without resuspension for iatrogenic urethral obstruction. *J Urol* 161: 198-199, 1999.

2. **Foster HE Jr**: Re: Effect of bladder management on urological complications in spinal cord injured patients. *J Urol* 163: 772, 2000.

## Abstracts

1. **Foster HE Jr**, Ritchey ML, Bloom DA and McGuire EJ: Evaluation and management of neurogenic vesical dysfunction in children with sacral agenesis. *J Urol* 149: 260A, 1993.
2. Smith SD, **Foster HE Jr**, Wheeler MA and Weiss RM: Decreased nitric oxide synthase activity in interstitial cystitis. *NIDDK Symposium on Women's Urological Health Research*. pp. 134, 1994.
3. Smith SD, **Foster HE Jr**, Wheeler MA and Weiss RM: Urinary nitric oxide synthase (NOS) activity is decreased in patients with interstitial cystitis (IC). *FASEB J* 8: A361, 1994.
4. Smith SD, **Foster HE Jr**, Wheeler MA and Weiss RM: Decreased nitric oxide synthase activity in interstitial cystitis. *J Urol* 151: 283A, 1994.
5. **Foster HE Jr**, Takigawa H, Saito M, Fukumoto Y, Weiss RM, and Latifpour J: Autoradiographic localization of beta adrenergic and muscarinic cholinergic receptors in diabetic rat prostate. *J Urol* 151: 298A, 1994.
6. Latifpour J, Kamai T, **Foster HE Jr**, Fukumoto Y, and Weiss RM: Regional differences in the property of muscarinic cholinergic receptors in rat vas deferens. *FASEB Journal* 9(4): 3886, 1995.
7. Smith SD, Wheeler MA, **Foster HE Jr**, and Weiss RM: L-arginine decreases interstitial cystitis symptoms while increasing urinary nitric oxide synthase activity. *FASEB Journal* 9(4): 5344, 1995.
8. Wheeler SA, Smith SD, Weiss ED, and **Foster HE Jr**: Effect of urinary tract infection and interstitial cystitis on urinary cyclic GMP levels. *J Urol* 153: 265A, 1995.
9. Saito M, Nakamura I, **Foster HE Jr**, Fukumoto Y, Yoshida M, Weiss RM, and Latifpour J: Diabetes increases the expression of endothelin receptors in rat ureter. *J Urol* 153: 462A, 1995.
10. Nishi K, Saito M, **Foster HE Jr**, Yoshida M, Ueda S, Weiss RM, and Latifpour J: Diabetes-induced alterations in the properties of alpha-1 adrenergic receptors in the rat prostate. *FASEB J*. 10, A203, 1996.
11. Saito M, Nishi K, Miyagawa I, **Foster HE Jr**, Fukumoto Y, Weiss RM, and Latifpour J: Characterization of endothelin receptors in vas deferens of diabetic rats. *FASEB J* 10: A203, 1996.
12. Smith SS, Wheeler MA, **Foster HE Jr**, and Weiss RM: Efficacy of oral L-arginine treatment for interstitial cystitis: the role of nitric oxide synthase. *J Urol* 155: 439A, 1996.
13. Nishi K, Saito M, **Foster HE Jr**, Yoshida M, Ueda S, Weiss RM, and Latifpour J: Diabetes-induced alterations in the properties of alpha-1 adrenoreceptors in the rat vas deferens. *J Urol* 155: 619A, 1996.

14. **Foster HE Jr**, Allison S, and Weiss RM: The relationship between level of improvement with biofeedback therapy to patient satisfaction and quality of life. *J Urol* 155: 638A, 1996.
15. Siegel, SB and **Foster HE Jr**: Long term results of pubovaginal sling for stress urinary incontinence. *J Urol* 157: 460A, 1997.
16. Saito M, **Foster HE Jr**, Wada Y, Weiss R M and Latifpour J: Endothelin receptors in diabetic rabbit prostate. *FASEB J.* 11:A505, 1997.
17. Saito M, **Foster HE Jr**, Wada Y, Miyagawa I, Weiss RM and Latifpour J: Endothelin receptors in diabetic rat bladder dome. 27th Annual Meeting International Continence Society, Yokohama, Japan, 1997.
18. Saito M, Latifpour J, Wada Y, **Foster HE Jr**, Miyagawa I, and Weiss RM: Age related changes in endothelin receptors in rabbit lower urinary tract. 27th Annual Meeting International Continence Society, Yokohama, Japan, 1997.
19. Latifpour J, Wada Y, Wang Z J, Nishi K, Saito M, Ueda S, **Foster HE Jr**, and Weiss RM: Ontogeny of endothelin receptors in rabbit lower urinary tract. *FASEB J.* 12: A52, 1998.
20. Wada Y, Latifpour J, Wang ZJ, Nishi K, Saito M, Ueda S, **Foster HE Jr**, and Weiss RM: Age related changes in endothelin receptors in rabbit renal pelvis. *FASEB J.* 12: A53, 1998.
21. Kusek JW, Bain R, Burrows PK, **Foster HE Jr**, Ramsdell J, Pavlik V, Nyberg L, Ahrens A, and MTOPS investigators: The prevalence of hypertension in non-hispanic (NH) black, NH white and hispanic men participating in a clinical trial of medical therapy for benign prostatic hyperplasia (BPH). 13th International Interdisciplinary Conference on Hypertension in Blacks. 1998
22. Fornaro M, Manzotti M, Zheng D, Slear AE, **Foster HE Jr**, Tallini G and Languino LR: Inhibition of prostate cell proliferation by the  $\beta_1C$  integrin. *Biology of Prostate Growth Symposium.* 1998
23. Korting GE, Smith SS, Wheeler MA, **Foster HE Jr**, and Weiss RM: A randomized double-blind trial of oral L-arginine for treatment of interstitial cystitis. *J Urol* 159: 306A, 1998.
24. **Foster HE Jr**, Wang Z, Wada Y, Smith SD, Saito M, Weiss RM, and Latifpour J: Expression and localization of basic fibroblast growth factor in diabetic rat prostate. *J Urol* 161: 231, 1999
25. Saito S, Wada Y, Wang Z-J, **Foster HE Jr**, Smith SD, Nishi K, Weiss RM and Latifpour J. Gene expression, localization, and pharmacological characterization of endothelin receptors in diabetic rat prostate. *J Urol* 161: 350, 1999.

26. Ikeda K, Wada Y, Wang Z-J, **Foster HE Jr**, Weiss RM and Latifpour J: Experimental diabetes-induced regression of the rat prostate is associated with an increased expression of transforming growth factor- $\beta$ . *Eur Urol* 36: 532, 1999.
27. Ikeda K, Latifpour J, Wada Y, Wang Z-J, **Foster HE Jr**, Sanematsu H, Shin D, Afiatpour P, Ueda S and Weiss RM: Regulatory effect of experimental diabetes on the expression of endothelin receptor subtypes and their gene transcripts in the rat adrenal gland. *J Urol*. In press.
28. Ikeda K, Wada Y, Pasha MS, Wang Z-J, **Foster HE Jr**, Yoshida M, Weiss RM and Latifpour J: Upregulation of transforming growth factor-beta and its receptors at both protein and gene transcript levels is associated with prostatic regression in the experimental diabetic rat. *J Urol* 163: 211, 2000.
29. **Foster HE Jr**, Ikeda K, Derweesh I, Sanematsu H, Flynn S, Weiss RM, and Latifpour J: The expression of endothelin receptor subtypes and their mrnas in human prostate *J Urol* 163: 212, 2000.
30. Ikeda K, Wada Y, Wang Z-J, **Foster HE Jr**, Sanematsu H, Shin D, Afiatpour P, Ueda S, Weiss RM and Latifpour J: Differential regulation of endothelin receptor subtypes and their gene transcripts in rat adrenal gland: effect of experimental diabetes. *FASEB J* 14: A571, 2000.
31. Ikeda K, Wada Y, Pasha MS, Wang Z-J, **Foster HE Jr**, Yoshida M, Weiss RM and Latifpour J: Prostatic regression in streptozotocin-diabetic rat is associated with an upregulation of transforming growth factor-beta and its receptors. *FASEB J* 14: A363, 2000.
32. Takahashi W, Afiatpour P, Latifpour J, **Foster HE Jr**, Weiss RM. Developmental changes in the functional, biochemical and molecular properties of rat bladder endothelin receptors. *J Urol* 167: 44, 2002 April.
33. Takahashi W, **Foster HE Jr**, Afiatpour P, Ueda S, Weiss RM, Latifpour J. Regulatory effect of castration on the expression of endothelin receptors and their gene transcripts in rat seminal vesicle. *J Urol* 167: 242, 2002 April.
34. **Foster HE Jr**, Hemani M, Derweesh IH, Pouresmail M, Sanematsu H, Yono M and Latifpour J: Identification and characterization of endothelin receptors in human prostate using autoradiographic, immunohistochemical and immunoblotting techniques. *J Urol* 171(4): 347, 2004 April.
35. Shnorhavorian M, **Foster HE Jr**. Surgical Management of Complex Neurogenic Urinary Incontinence in Female patients: The 10-Year Yale Experience. *NE AUA Annual Mtg*: 144, 2004 Sept.

## Book Chapters

1. **Foster HE Jr** and Lytton BL: The Diagnostic Evaluation of Prostate Cancer. In: Urologic Cancer. Peschel RE, Ernstoff M and Heaney J (Eds). WW Norton & Company, New York, NY, 1997, pp. 48-61.
2. **Foster HE Jr** and McGuire EJ: Urethrolysis. In: Urinary Incontinence. O'Donnell, P.D. (Editor). Mosby-Year Book Inc, St. Louis, MO, 1997, pp. 253-257.
3. **Foster HE Jr** and Lytton BL: The Diagnostic Evaluation of Prostate Cancer. In: Advances in Prostate Cancer. Blackwell Science Company.
4. **Foster HE Jr**: Female Urology and Incontinence. In: Weiss RM, George N Jr, and O'Reilly PH (Eds.): Comprehensive Urology, Mosby International Ltd., London, England, 2001, pp. 477-492.
5. Weiss, RM and **Foster HE Jr**: Physiology of the Ureter, Bladder, and Urethra. In: Massry, SG and Glasscock, RJ (Eds.): Textbook of Nephrology, 4th Edition. Lippincott Williams & Wilkins, New York, NY, 2001, pp. 122 - 129.
6. **Foster HE Jr**: Transurethral Resection of the Prostate. In: Management of Benign Prostatic Hypertrophy. Kevin T. McVary, M.D. (Editor). Humana Press, Totowa, NJ, 2003, pp. 163-193.

## FUNDED RESEARCH EFFORTS

1. VA Cooperative study #359: A clinical trial comparing the safety and efficacy of alpha blockade and androgen suppression for the treatment of benign prostatic hyperplasia. **Principle Investigator** West Haven VA Site. March 1993 to March 1995.
2. NIH DK-93-19: Nitric oxide transduction mechanisms in urinary tract infections and interstitial cystitis. Investigator (15%). Robert Weiss, Principle Investigator. September 1993 to September 1998.
3. NIH, 5U01 DK49963: Medical therapy in benign prostatic hyperplasia: Full scale trial. **Principle Investigator** Yale University. April 1995 to April 2002.
4. NIH DK-96-005: Molecular regulation of prostate growth by integrins. Investigator (10%). Luciano Languino, Principle Investigator. Funded for 1997 to 2002.
5. Doxazosin Investigators and Consultant Educational Exchange (DICE): The effects of chronic administration of alpha antagonists on the rat prostate. **Principle Investigator**. Funded January to August 1998.
6. NIH/NIDDK, 2 R01 DK42530-09: "Diabetes-Induced changes in the Genitourinary Tract"

Role: **Co-Investigator** (10%). Dr. Latifpour is Principle Investigator. Sept 2001 to August 2005.

7. NIH/NIDDK, 5 U01 D063862: Phytotherapy for the Treatment of BPH symptoms. Principle Investigator. Sept 2003 to March 2010.